156 related articles for article (PubMed ID: 26133466)
1. Identification of urine protein biomarkers with the potential for early detection of lung cancer.
Zhang H; Cao J; Li L; Liu Y; Zhao H; Li N; Li B; Zhang A; Huang H; Chen S; Dong M; Yu L; Zhang J; Chen L
Sci Rep; 2015 Jul; 5():11805. PubMed ID: 26133466
[TBL] [Abstract][Full Text] [Related]
2. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling.
Kreunin P; Zhao J; Rosser C; Urquidi V; Lubman DM; Goodison S
J Proteome Res; 2007 Jul; 6(7):2631-9. PubMed ID: 17518487
[TBL] [Abstract][Full Text] [Related]
3. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
4. Urinary protein biomarkers in the early detection of lung cancer.
Nolen BM; Lomakin A; Marrangoni A; Velikokhatnaya L; Prosser D; Lokshin AE
Cancer Prev Res (Phila); 2015 Feb; 8(2):111-9. PubMed ID: 25416410
[TBL] [Abstract][Full Text] [Related]
5. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
6. ETS1 regulates Twist1 transcription in a Kras
Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
[TBL] [Abstract][Full Text] [Related]
7. Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.
Xie F; Li P; Gong J; Tan H; Ma J
Clin Transl Oncol; 2018 May; 20(5):591-598. PubMed ID: 28956302
[TBL] [Abstract][Full Text] [Related]
8. KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancer.
Yu T; Chen X; Zhang W; Liu J; Avdiushko R; Napier DL; Liu AX; Neltner JM; Wang C; Cohen D; Liu C
Cell Death Differ; 2016 Feb; 23(2):207-15. PubMed ID: 26113043
[TBL] [Abstract][Full Text] [Related]
9. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
10. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
Xu Y; Zong S; Gao X; Zhang H; Wang B; Li P; Liu T; Li S
Gene; 2019 Mar; 688():1-6. PubMed ID: 30415007
[TBL] [Abstract][Full Text] [Related]
12. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.
Bleau AM; Freire J; Pajares MJ; Zudaire I; Anton I; Nistal-Villán E; Redrado M; Zandueta CN; Garmendia I; Ajona D; Blanco D; Pio R; Lecanda F; Calvo A; Montuenga LM
Int J Cancer; 2014 Dec; 135(11):2516-27. PubMed ID: 24473991
[TBL] [Abstract][Full Text] [Related]
13. IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling.
Wang YA; Sun Y; Palmer J; Solomides C; Huang LC; Shyr Y; Dicker AP; Lu B
Mol Cancer Res; 2017 Jul; 15(7):896-904. PubMed ID: 28330997
[TBL] [Abstract][Full Text] [Related]
14. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
15. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
Gu L; Deng ZJ; Roy S; Hammond PT
Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
[No Abstract] [Full Text] [Related]
16. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis.
Yang S; Xia J; Yang Z; Xu M; Li S
Cancer Treat Res Commun; 2021; 27():100311. PubMed ID: 33465560
[TBL] [Abstract][Full Text] [Related]
18. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer.
Mazzone PJ; Wang XF; Lim S; Choi H; Jett J; Vachani A; Zhang Q; Beukemann M; Seeley M; Martino R; Rhodes P
BMC Cancer; 2015 Dec; 15():1001. PubMed ID: 26698840
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
